

Lente insulin davis pdf

The problem of fasting hyperglycemia remains unresolved in the injection regimen, which is currently used twice a day. Human ultra-lent insulin is a longer period of time than human lenses and differs only in the nature of the zinc-insulin complex. In a six-month double-blind cross-examination, these insulins were compared in 66 patients randomized to human superlent or human lente insulin given with human soluble insulin in a twice-daily injection regimen. Patients were seen monthly and crossed after 3 months of treatment. The fasting blood sugar concentration of the ultralento regimen was significantly lower than that of lenteredimen, and the difference was statistically significant (6.6+/- 0.5 vs. 8.2+/- 0.5 mmol I-1, p less than 0.05), but only in patients with an emptying concentration below the median. Glycosylized hemoglobin was the same in both regimens (9.3 +/- 0.2%). The night ultra-rent dose was slightly lower than the evening lente dose (14.9 +/- 0.8 vs. 15.5 +/ - 0.8 U, less than p 0.05), supporting the reduced effect of super rent on fasting blood sugar concentrations. However, the incidence of severe hypoglycemic events was high at the ultra-rent regimen (0.38 +/- 0.10 vs. 0.09 +- 0.04). events per month +- 0.04 events, less than p 0.02), the majority of nightly events occurring between 0500 hours and breakfast. We conclude that ultralentoin insulin can give improved fasting blood sugar levels, but does not provide clinical benefits for human lente insulin in twice-daily injection regimens in patients with more pronounced fasting hyperglycemia or nightly hypoglycemia. Safety, efficacy, and cost-effectiveness of long-acting insulin in patients with type 1 diabetes mellitus: a systematic review and network meta-analysis. Trico AC, Ashore HM, Antony J, Bayen J, Veroniki AA, Isara Nuugwai W, Harrington A, Wilson C, Tsolos S, Subia C, Yu CH, Hutton B, Hoch JS, Hemmelgaan BR, Moher D Majumdar SR, Strauss SE. Trico AC, et bmJ. October 1, 2014; 349:g5459. Doi:10.1136/bmj.g5459. Bmj. 2014. PMID: 25274009 Free PMC Article. Review. Killing, Courtney and other insulin zinc suspensions (Lente insulin) Davis' drug guide, 16th, F.A. Davis Company, 2020. Davis Drug Guide - OLD - Use 2.0, www.drugguide.com/ddo/view/Davis-Drug-Guide/109056/all/insulin zinc suspension lente insulin . Killing C, Sanoski CA, Valleland AH. Insulin zinc suspension (lente insulin). Davis' drug guide. F.A. Davis Company;2020. January 18, 2021. Killing, C., Sanoski, C.A., and Valleland, A.H. (2020). Insulin zinc suspension (lente insulin). In Davis's Drug Guide (16th edition). Acquired from January 18, 2021 by F.A. Davis CompanyC, Sanoski CA, Valleland AH. Insulin zinc suspension (Lente insulin) [Internet]. In: Davis' Drug Guide.F.A. Davis Company; 2020. [Citation 2021 January 18].. Available from: Article title in AMA citation format, sentence case MLAAMAAAVANCOUNTY - ELEC T1 - Insulin zinc suspension (Lente insulin) ID - 109056 A1 - Killing. Courtney. AU -Sano Suki, A, AU - Vareland, April Hazard, BT - Davis Drug Guide UR - PB - F.A. Davis Company ET - 16 DB - Davis Drug Guide - OLD - USE 2.0 DP - Unbound Medicine ER - Class: Rapid Acting Insulin ATC Class: A10 AB04 VA Class: HS501 Chemical Name: 28B-I-Lysine-29B-I-Proline (Human) Molecular Formula: C257H383N65O77S 6 CAS Number: 133107-64-9 Brand: Humarogun Diabetes Therapeutics; Rapid-acting biosynthetic human insulin analog. 1 2 8 13 51 145 Used to control hyperglycemia in the management of diabetes. 1 3 6 12 47 75 77 In patients with type 781 diabetes, it is commonly used as a medium or long-acting insulin preparation (i.e. isofan[NPH] insulin human, insulin squirrel proprotamine [humalogmix 75/25 as a fixed combination], insulin zinc [lent], extended insulin human zinc [ultra rent], providing edible glycemic control.1 73 74 76 7 In patients with 77 78 79 81 96 144 145 159 160 161 165 type 2 diabetes can be used without long-acting insulin when administered with sulkhonyl urea. 1 158 159 160 161 165 Patients with low glycocylized hemoglobin levels, including patients with type 1 diabetes who want a more flexible injection schedule, and some residual β -cell functions that provide basal insulin levels during meals Patients with recently developed type 1 diabetes .6 12 56 59 74 77 78 79 81 144 145 years of age, obesity, types of diabetes for glycemic reactions do not seem to differ in patients receiving insulin rispro and insulin humans. 1 51 Some clinicians suggest that patients who are well controlled with conventional short-function insulin preparations without frequent hypoglycemia should not be routinely switched to insulin lispro.74 144Do. To improve the accuracy of administration in pediatric patients who do not administer insulin lispro in a fixed combination with insulin lispro IV.a, dilute to a ratio of 1: 10 or 1: 2 to obtain aseptic dilution solution and drug compatibility information provided by the manufacturer. See compatibility under stability, using a conventional insulin syringe or injection pen (e.g. Becton Dickinson [B-D] pen, fumaroglupene, novo) immediately (i.e. within 15 minutes before or after meals) administration by sub-Q injectionNovoPen).1 1155 156 157 Generally administered in multiple daily doses with regimens containing intermediate or long-acting insulin (e.g. NPH, Lente, Ultralente) Manage insulin rispropro within 15 minutes before morning and evening meals twice a day with .1 72 74 insulin risproamine (humalog mix 75/25) given in the morning and/or evening to provide. To avoid damage to the thigh, or upper arm.g tissue, the next injection is given at least 1/2 inch from the previous injection site. Management by continuous sub-O injection using an external controlled injection device. 1 Recommended for use with Disetronic 3.15 mL insulin reservoir), decetronic D-TRON, or decetronic D-TRONplus external injection pump (decetronic With rapid injection set) and MiniMed model 506, 507, or 508 pump MiniMed Polyfin infusion set.1 Provides fast or short acting insulin at continuous basal rate throughout the day with patient-initiated birth of insulin before meals. Regularly adjusting the dose based on blood sugar decision.1 n Usually, the total insulin requirement for children with type 1 diabetes ranges from 0.2 to 1 unit / kg (generally 0.5 to 0.8 units / kg per day). Adolescents in the 22 28 47 z growth stage may require an initial insulin dose of 1-1-1.5 units / kg. Between 26 and 64 percent of total insulin requirements are provided by Insulin Lispro. With the rest provided by medium or long-acting insulin. 1 In clinical trials, pre-administration of insulin rispro injections accounts for about 66% of the daily insulin dose, with the rest given as basal infusions. Adjusting the dosage regularly based on blood sugar decisions. 1 Usually, the daily total insulin requirement for patients with type 1 diabetes does not have a recommended value for a specific dosage by the manufacturer. Between 39 and 66 percent of the total insulin rispro, the rest by middle or long-acting insulin, and the rest by diabetics with type 2 diabetes who are not controlled by middle-acting or long-acting insulin, suggesting that some clinicians begin precursor therapy with insulin. Or fast-acting insulin, a precursor injection that contains 40-50% of the total insulin dose. Regularly adjust the dose based on blood sugar determines. 1 glucose monitoring is especially important for patients who receive insulin via an external infusion pump. In patients with type 1.1 diabetes, precursor administration of insulin rispro injections is used in clinical trials, and the rest is basic in.16 m. regularly adjusting the dose blood sugar decision.a Initially, 0.3-0.5 units/kg given daily to twodivision doses (before morning and evening meals) is used in patients with type 2 diabetes. In order to achieve the target fasting blood sugar concentration every 2-3 days for 2-4 units of infusion per day to achieve the target, the average daily maintenance insulin dose was 0.46-0.66 units /kg.159 v w x yIn patients in patients with type 1 diabetes in clinical trials. The daily maintenance insulin dose achieved on average is 0.64 units /kg.x insulin rispro has a shorter duration of onset and action than insulin humans (regular) Type 1 diabetes mellitus patients need longer acting insulin to maintain sufficient night and precursor glycemic control. Effects include patients fasting or patients with defective antimodule responses (e.g., patients with autonomic disorders, adrenal or pituitary failure, β patients receiving adrenaline blockers). Rapid changes in serum glucose concentration can cause symptoms of hypoglycemia regardless of glucose concentration. Diabetic neuropathy, 1 and / or hiding catecholamine-induced symptoms of hypoglycemia (e.g., vibration, palpitations) 1 Use careful insulin therapy in patients with a history of hypoglycemia or relapsing, severe hypoglycemia. Higher target blood glucose concentrations (e.g., fasting blood sugar levels of 140 mg / dL and post-meal concentrations of 200 to 250 mg / dL for 2 hours) are recommended in these patients. Local reactions (e.g., erythema, pruritus, swelling) reported .1 Generalized hypersensitivity reactions (e.g., rashes, shortness of breath, wheezing, hypotension, tachycardia, and diaphores) are not reported. Ubu-noThe reported reaction and generalized myalgia in the use of m-cresol are excisors in the formulation. Compare the benefits to the risk of patients with a history of hypersensitivity to other insulins. 51 glandular atrophy or enlargement of subcutaneous adipic tissue can occur at the site of frequent insulin injections. It is not known whether insulin rispro is distributed in milk, such as those receiving potassium-lowering drugs, but other insulins (e.g. insulin humans) may require adjustments to the .1 insulin lispro dosage and/or dietary plan &It; when used in lactating women. ,1 51 74 and preliminary data suggest that there is no abnormal effect of insulin squirrel protherapy in adolescents receiving the drug. 74 118 144 145 149 150 151 Adjustment of basal insulin dose may be necessary. An increase in the incidence of hypoglycemia associated with intensive insulin therapy may increase the probability of stroke and heart attack in such patients. Hypoglycemic reactions can mimic cerebrovascular disorders. Patients with type d type 2 diabetes may be more vulnerable to serious consequences of hypoglycemia (e.g., redness, seizures, falls, stroke, silent ischemia, MI, or sudden death) due to an increased incidence of large vascular disease. The response \geq 65-year-old patients does not seem to differ from that of young adults. Insulin of animal origin .1 2 3 6 9 10 51 73 144 145 16514 peak plasma insulin concentration, which is absorbed more rapidly than soluble preparations of human or insulin, occurs earlier than in humans (50-120 minutes). A fixed combination of insulin rispro and insulin lisprotamine (humaroglumix 75/25), peak serum insulin concentration was observed at 30-240 minutes (median: 60 minutes). It was absorbed more rapidly than the fixed combination of 165 insulin (Humulin 70/30). The degree of insulin activity, and duration (e.g., injection techniques, presence of insulin antibodies, injection site, tissue blood supply, temperature in insulin preparations, excisors, and differences between individuals and individuals) 1 19 47 74 83 After sub-Q injection of insulin repro, the onset generally ranges from 0.25-0.5 hours to 0.5 hours. In humans, the peak glycemic response to .1 3 9 51 73 74 83 insulin rispro or insulin humans occurs in 0.5-2.5 or 1-5 hours, respectively, Sub-Q administration after .1 3 9 51 73 74 83, respectively, the duration of hypoglycemic action of insulin rispro is 3-6.5 hours compared to 6-10 hours in insulin humans. Humulin 70/30.165 The presence of liver damage does not affect the absorption of patients with type 2 diabetes. However, other insulins (e.g. insulin humans) do not seem to cross the placenta of pregnant women with gestational diabetes mellitus. The distribution of 164 insulin rispro is the same as that of insulin humans, and 0.26-0.36 L/kg.1 liver damage does not affect the distribution of patients with type 2 diabetes mellitus. The metabolism of insulin rispro is the same as that of insulin humans, but insulin humans, but insulin humans, but insulin humans, but insulin humans. patients with renal or liver failure., 2-8°C.1 19 156 165 Do not freeze. If frozen, discard the vial or cartridge. &It;30°C for= up= to= 28= days.1= 19= 51= 81= 155= protect= from= heat= and= light.1= 155with= disposable= injection= pens= of= insulin= lispro= in= fixed= combination= with= insulin= lispro= protamine = (humalog = mix = 75/25 = pen) = that = are = in = use = to = 10 = days. 160 = 165 = protect = from = light = and = excessive = heat. 160 = 165 = protect = heat. 160 = 165days= when= stored= at= 5°c= or= after= 14= days= when= stored= at= 30°c.165 should= not= expose= insulin= lispro= in= the= external= injection= device= to= temperatures=> and catheters), dicetronicstron or dicetronics-TRONplus cartridge adapters, and insulin lispro in pump reservoirs. Select a new infusion site at least every 48 hours. 1The 3mL cartridge used in decetronicstron or disetronics troplus insulin pumps must be discarded. Continuous sub-Q injection in several external injection pump systems (i.e., dicetronic H-TRON, mini-mame model 504 pumps) does not reveal changes in potency, purity, or physical stability of the drug </30°C>Within each of these devices 48 hours .51 81 146 163 However, insulin rispro precipitation on the infusion catheter (ie, silhouette, soft set catheter) minimizes several external pump systems (i.e., dicetronic H-TRON V-100, dicetronic H-TRON V-100, dicetronic H-TRON V-100, 507C pumps). For information about systemic interactions caused by 167 combinations, see Interactions. Tendency of insulin.1 Insulin mixture should not be administered IV.1, or when administered via an external sub-Q controlled infusion device (pump), other insulin and insulin rispro should not be mixed. 1Excipients formulations in commercially available drugs may have clinically significant effects in some individuals; 1. Eli Lilly and company. Humalog (insulin rispro, [rDNA origin]) injection prescription information. INDIANAPOLIS, IN; June 2, 2004 2. Howie DC, Bowscher RR, Brunel RL et al. [Lys (B28), Pro (B29)-Human insulin: a rapidly absorbed analogue of human insulin. Diabetes. 1994;43:396-402. 3. Howie DC, Bowsher RR, Brunel RL et al. [Lys (B28), Pro (B29)]-Human Insulin: Effects of injection time on post-meal blood sugar. Clin Pharmacol Cir 1995;58:459-69. 4. Chance RE, DiMarchi RD, Frank BH, and others; Eli Lilly and Company, assigned to. European patent application No. 383472 for the preparation of insulin with modified related and biological properties. August 22, 1990. Barge, Castillo KR, Shade DS. Dietary composition is a determining factor for lispro-induced hypoglycemia in IDDM. Diabetes care, 1997:20:152-5, 6. Panpanelli S. Torrone E. Lari C et al. Improved post-meal metabolic control after subcutaneous injection of short-function insulin analog in IDDM for a short period with residual pancreatic B cell function. Diabetes care. 1995;18:1452-9. 7. Reproductive and developmental toxicity studies of Buelke Sam J, Bird RA, Hoyt JA et al. LY275585, Lys (B28), pro (B29) - human insulin in CD rats. J am Col Xycotor.1994;13:247-60. 8. Role of C-terminal B-chain remains in insulin set by Sizak E, Bealz JM, Frank BH, etc.: hexagonal LysB28ProB29 - structure of human insulin. Structure. 1995;3:615-22. 9.Torlon E, Fanelli C, Lambotti AM et al. Pharmacodynamics and glucose-to-regulation after subcutaneous injection of monomedic insulin analogsDo it with IDDM. Diabetes. 1994;37:713-20. 10.Betts JL. Fast-acting human insulin analogues: promising innovations in diabetes care. Diabetes Eduk. 1995;21:195, 197-8, 200. 11.Troutman ME. Effects of insulin analogues [LYS(B28)] and [Pro (B29)] on blood sugar control Home Mettab Res 1994; 26:588-90. 12. Pututner A, Küstner E, Forst T, and others for the German Insulin Squirrel Pro/IDDM Research Group. Intensive treatment of insulin therapy with insulin rispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. Excrine Endocrine Diabetes.1996;104:25-30. 13. Changes in the relevant properties of insulin due to amino acid substitution of Brems DN, Alter LA, Beggage MJ et al. Protein Eng. 1992; 5:527-33. 14. Preparation of insulin in consideration of structural homing with insulin-like growth factors such as Dimarchi RD, Chance RE, Long HB I. Horm Res. 1994; 41 (Sapul 2): 93-6. 15. Antimodulation hormone responses and symptoms during hypoglycemia induced by Jacobs-Madjim, Salobial B, Pop Snyder's C et al pigs, human normal insulin, and Lys (B28), a human insulin analogue (insulin rispro) in healthy male volunteers. Diabetes drugs 1997;14:248-57. 16. Zimmerman J. 12-month chronic toxicity study LY275585 (human insulin analog) was administered subcutaneously to Fisher 344 rats. Diabetes. 1994; 43 (Sapul 1): 166A. 17. Immunogeneticity of biosynthetic human LysPro insulin was compared with native sequences of human and purified pig insulin in rhesus monkeys immune over a six-week period. Alznai Mittelforschung. 1995;45:524-8. 18. Sleeker LJ, Brooke GS, Chance RE Et Al Insulin and IGF-I Analog: New Approach to Improved Insulin Pharmacokinetics. In: Lurois D, Lizada MK eds. Current Direction in Insulin-Like Growth Factor Research.New York: Plenum Press; 1994:25-32. 19. American Diabetes Association. Insulin administration. Diabetes care. 1997; 20 (Sapul 1): S46-9. 20. European IDDM Policy Group 1993. Consensus Guidelines for The Management of Insulin-Dependent (Type 1) Diabetes. Diabetes drugs 1993; 10:990-1005. 21.Diabetes Control and Complications Study Group. Effects of intensive care of diabetes mellitus on the development and progression of long-term complications in insulin-dependent diabetes N Engle J. Med 1993;329:977-86.22. Campbell PJ, I May. Practical guide to intensive insulintherapy. Am J Medsay 1995;310:24-30. 23.Ziegler O, Coropping M, Louis J. Self-monitoring of changes in blood sugar and insulin volume in type 1 diabetes Rescrympect.1993;21:51-9. 24. American Diabetes Association. Medical standard diabetes care for diabetic patients. 1997; 2000:23 (Sapul 1): S32-42. 25. Orevski JM. Sugar urine disease. Ins: Winger Don JB, Smith LH Jr., Bennett JC, Eds. Cecil medicine textbook. 19th ed.Philadelphia: WB Sanders Inc.; 1992:1291-1310. 26. Step-by-step diabetes management by Mazze RS, Etzweiler DD, Strok E, et al. Diabetes care. 1994; 17 (Sapul 1): 56-66, 27. Foster DW. Sugar urine disease, Ins: Fauci AS, Braunwald E, Isselbacher KJ et al., eds, Harrison's principles of internal medicine, 14th Edition. New York: McGrow Hill Co., Ltd. 1998;2060-81, 28. Koda Kimble MA, Carlisle BA, Diabetes, Ins: Young LY, Koda Kimble MA, eds, Applied treatment: clinical use of the drug. 6th Vancouver, WA: Applied Therapeutics Inc.; 1995:48-1-48-62.29. Turner R, Cal C, Holman R, and others. British Prospective Diabetes Study 17: A nine-year update on a randomized, controlled trial on the effects of improved metabolic control on complications of noninsulin-dependent diabetes. 30. Colwell JA. Realization of Intensive Insulin Management in Noninsinsin-Dependent Diabetes: Impact of Veterans Cooperative Study on Glycemic Management and Complications in NIDDM Ann Intern Med 1996; 124:131-5. 31. Lanstedt Harin L, Bolinder J, Adamson U and others Comparative Diabetes Care for Secondary Sulfonyl Urea Failure Combined with Bedtime NPH or Prelangeal Regular Insulin and Glybenkramide. 1995;18:1183-6. 32.1ki Järvinen H, Kawpira M, Kujansu E et al. Comparison of insulin regimens in noninsulin-dependent diabetics N Engle J Med 1992;327:1426-33. 33. Comparative diabetes care of insulin on the presence or absence of continuation of oral hypoglycemic agents in the treatment of secondary insufficiency in NIDDM patients such as Chau CC, Sorensen JP, Tsang LWW. 1995;18:307-14. 34. Klein R, Klein BEK, Moss SE and others. Glycosylized hemoglobin predicts the incidence and progression of diabetic retinopathy. Jama. 1988;260:2864-71.35. American Association of Health System Pharmacists. ASHP Therapeutic Position Statement on Strict Glycemic Control in Insulin-Dependent Diabetics Am J Health Sisto Farm 1995;52:2709-11. 36.Reichhardt P, Nilsson BY, Rosenqvist U. Effect of long-term enhancement of insulin treatment for the development of miquanular complications of diabetes. N Engle J. Med 1993;329:304-9. 37. American Diabetes Association. Diabetes control and complications test meaning. Diabetes care. 1997; 20 (Sapul 1): S620-4. 38. Henry RR, Genuth S. Forum 1: Current Recommendations on Strengthening Metabolic Control in Noninsinsin-Dependent Diabetes. Anne Intern Med 1996;124:175-7. 39. Insulin intensive therapy by Okubo Y, Kishikawa H, Araki E, and others prevents the progression of diabetic miquarovascular complications in non-insulin-dependent diabetic patients: a randomized, forward-looking 6-year study. Diabetes Resclinect.1995;28:103-17. 40. Klein R, Klein BEK, Moss SE. Relationship of glycemic control to diabetic miergiscular complications in diabetes mellitus. Anne Intern Med 1996;124:90-6. 41. Henry RR. Glucose control and insulin resistance Ann Intern Med in non-insulin-dependent diabetes med 1996; 124:97-103. 42. Hafanitz PJ, Hafanitz JH. Carbohydrate. In: Henry JB, ed.. By Todd Sanford Davidson Clinical Diagnostics and Testing Management 17th ed.Philadelphia: WB Sanders Inc.; 1984:165-179. 43. Cardiovascular Risk Ann Intern Med in Exogenous Insulin Administration and Non-Insulin Dependence and Insulin-Dependent Diabetes Med 1996; 124:104-9.44. Laakso M. Risk of coronary heart disease in glycemic control and noninsulindependent diabetics: Finnish study. Anne Intern Med 1996;124:127-30. 45. Conif RF, Shapiro JA, Seaton tuberculosis. Long-term efficacy and safety of acarbose in the treatment of obese people with non-insulin-dependent diabetes mellitus 1994;154:2442-8. 46. Zimmerman BR. Prevention of long-term complications: effects on combination therapy with acarbose. 1992; 44 (Sapul 3): 54-60. 47. Davis SN, Granner DK. Insulin, Oral Hypoglycemic Drugs, Pharmacology of Endocrine Pancreas. In: Hardman JG, Lindard LE, Molynoff PB, Goodman and Gilman are the pharmacological basis for therapeutics. 9th New York: McGrau Hill; 1996:1487-517. 48. Self-induced insulin hypoglycemia in bodybuilders such as Riverter JL, Tural C, Rosell A. Arch Intern Med 1994; 154:225-6. 49. Cryer PE, Geric JE. Regulation of glucose in diabetes, hypoglycemia, and intensive insulin therapy. N Engle J Med 1985;313:232-41. 50.Santiago JV. Intensive management of insulin-dependent diabetes: risks, benefits, unanswered questions. J. Klin Endkrinol Metab 1992; 75:977-82. 51.Eli Lilly and Company, Indianapolis, IN: Personal Communications. 52. Immunological effects of insulin lispro [Lys(B28) and pro (B29) human insulin) in IDDM and DIDDM patients previously treated with insulin. Diabetes. 1996;45:1750-4. 53. Henrichs HR, Anger H, Troutman ME and others. Treated with severe insulin squirrel pro.Lancet. 1996;348:1248. 54. Insulin lispro such as Perez A, Caixas A, Pays A and normal insulin have a similar effect on lipolytic action and VLDL composition in NIDDM. Diabetes. 1994;37 (Sapul 1): A168. 55. Treatment of type II diabetes mellitus using Anderson JH, Vignati L, Brunel RL. Insulin rispro is a rapidly absorbed insulin analogue. Diabetes. 1994; 37 (Sapul 1): A169. 56. Letiish MR, Ratters A, Schmidt H. [Lys(B28), Pro (B29)] Human Insulin: LysPro vs. Human Patients Treated with Normal Insulin: Quality of Life Assessment. Diabetes. 1994;37 (Sapul 1): A168. 57. Bojanon NJV, Jack DB. Type II diabetes: tips for managing elderly patients. Geriatrics. 1996;51:28-30,33-35. 58. Bergenstal R, Spencer M, Castle G et al. Insulin intensive management of type I and type II diabetes mellitus: comparison of [Lys(B28), pro (B29) human insulin] (LP) and normal human insulin] (LP) and normal human insulin (REG). Diabetes. 1994; 43 (Sapul 1): 157A. 59. Pre-dietary insulin analog insulin lispro vs. humulin R insulin treatment in young subjects with type 1 diabetes mellitus such as Garg SK, Carmaine JA, Brady KC. Diabetes drugs 1996;13:47-52. 60. Exercise-induced hypoglycemia in IDDM patients treated with short-acting insulin analogues such as Tuominen JA, Karonen SL, and Melamiz L. Diabetes. 1995;38:106-11. 61. Stepby-step and combination pharmacotherapy for the treatment of Levowitz HE.NIDDM. Diabetes care. 1994;17:1542-4. 62.Pharmacological treatmentHyperglycemia diabetes care in NIDDM. 1996;19:1510-18. (IDIS 355480).63. Expert Committee of the Canadian Diabetes Advisory Committee. Clinical Practice Guidelines for the Treatment of Diabetes. CMAJ.1992;147:697-712. 64. Reviewer's comments on metformin (personal observation). 65. Sulfonylurea failure in Holman RR, Steamson J, Turner RC.Type 2 diabetes mellitus: treatment with basal insulin supplements. Diabetes drugs 1987;4:457-62 66.McIsh AC, Munro JF, Duncan LJP. Treatment of hypoglycemic coma with glucagon, intravenous dexthose and mannitol infusion in 100 diabetic patients. Lancet. 1970;2:946-9. Alem R, Zogubi W. Insulin Overdose in 67.8 Patients: A Review of Insulin Pharmacokinetics and Literature. Medicine (Baltimore). 1985;64:323-32. 68.Astra USA Inc. 50% Dextrowth Injection, USP Prescribing Information.Westborough, MA; October 69, 1994 Chan JCN, Cockram CS. Impaired carbohydrate metabolism due to the drug.Adverse drug-reactive toxic substance Lev. 1991;10:1-29. 70.Pandet MK, Burke J, Gustafsson AB and others drug-induced disorders of glucose resistance. Anne Intern Med 1993;118:529-39. 71. Zacher RA, McPherson RA, Campos JM. Glucose measurement. Ins: Zacher RA, McPherson RA, Campos JM, eds. Clinical interpretation of Widman's clinical tests. 10th Edit. Philadelphia: FA Davis Company. 1991:323. 72.Eli Lilly and Company Humalog (Insulin Rispro, rDNA Origin) Injection (Vial) Patient Information. Indianapolis, IN; August 20, 2004, 73. Barnett AH, Owens DR. Insulin Analogue.Lancet. 1997;349:47-51. 74.Holleman F, Hookstra JBL. Insulin lispro. N Engle J Med 1997;337:176-83. 75. Anderson JH Jr., Brunel RL, Koivisto VA and others improved meal time treatment for diabetes using insulin analogues Clin Cir. 1997;19:62-72. 76. Jinman B, Tildesley H, Chiasson JL and other insulin lispro in CSII: results of a double-blind cross-examination. Diabetes. 1997;46:440-3. 77. Anderson JH Jr., Brunel RL, Keohane P and other insulin analogues improve post-dinner hyperglycemia and hypoglycemia in patients with noninsin-dependent diabetes. Arch Intern Med 1997;157:1249-55.78. Anderson JH Jr., Brunel RL, Koivisto VA and others. Decreased frequency of hyperglycemia and hypoglycemia after pregnancy in IDDM patients in insulin-analog treatment diabetes mellitus. 1997;46:265-70. 79. Anon Rispro, rapid onset insulin. Medlet Drug Sir. 1996;38:97-8. 80. Yale PM, Fassgänger RD, Kunze U and other human insulin analog insulin lispro improve insulin binding to circulating monocytes in intensively treated insulin-dependent diabetics. J. Klin Endkrinol Metab 1996; 81:2319-27. 81. Campbell LK, White JR. Insulin Lispro: Its role in the treatment of diabetes. Anne Pharmacozer1996; 30:1263-71. 82. Severe antibody-mediated human insulin resistance such as 82.Latella JT, Knip M, Paul R, and others: Successful treatment with insulin analog lispro. Diabetes care. 1997;20:71-3. 83.Ter-Burak-Eat, Woodworth JR, Bianchi R. and other injection sites have effects on pharmacokinetics and glucodynamics of insulin rispro and normal insulin diabetes care. 1996;19:1437-40. 84. Stella VJ. Chemical and physical basis that determines the instability and incompatibility of injectable drugs. J. Prolander Scitech 1986; 40:142-63. 85. Trissel LA. Handbook on Injectable Drugs. 9th-ranked Bethesda, MD: American Association of Health System Pharmacists Inc.; 1996:605-610. 86. National Diabetes Data Group. Classification and diagnosis of diabetes, and other categories of glucose insocia. 1979;28:1039-57. 87. American Diabetes Association. Office guide to the diagnosis and classification of diabetes and other categories of glucose insociating. 1995; 18 (Sapul 1): 4. 88. Expert Committee on Diagnosis and Classification of Diabetes. Report of the Expert Committee on The Diagnosis and Classification of Diabetes. Diabetes care. 1997;20:1183-97. 89. Diabetes control and complications testing research group. Hypoglycemia in diabetes control and complication trials. 1997;46:271-86. 90. Cohen P, Barzilai N, Rahman A, and others. Insulin effects on glucose and potassium metabolism in vivo: evidence of selective insulin resistance in humans. J. Klin Endkrinol Metab 1991; 73:564-8. 91. Calcidag K, Satman I, Dinkag N, and others. Comparison of metabolic control[LYS(B28), PRO(B29)]-IDDM with two different centralized regimens of human insulin (lispro) and NPH insulin. Diabetes. 1996; 39 (Sapul 1): A222. 92. Gibb DM, Foot ABM, May B and others. Double-blind cross-examination arch this child in human isofan or lente insulin-dependent diabetes mellitus 1990;65:1334-7. 93. Collezzy EJ, Jackson WPU. Pregnancy in established non-insulin-dependent diabetics. S Aflu Med J. 1980; 58:795-802. 94. American Diabetes Association. Preconception care for women with diabetes. Diabetes care. 1997; 20 (Sapul 1): S40-3.95. American Diabetes Association. Gestational Diabetes. Diabetes care. 1997; 20 (Sapul 1): S44-5. 96. Long-term effects of short-acting insulin respro in combination with human superlents in barge MR, Waters DL, Holcomb JH and others. J. Klin Endkrinor Metab 1997; 82:920-4. 97. Warning symptoms of hypoglycemia during treatment with human and pig insulin in diabetes mellitus such as Berger W, Honager B, Keller U, Lancet. 1989;1:1041-4. 98. Colagiuri S, Miller JJ, Petkuz P. Double-blind crossover comparison of human and pig insulin in patients reporting a lack of recognition of hypoglycemia. Lancet. 1992;339:1432-5. 99. Anon. Hypoglycemia and human insulin drug sabre. 1993;31:7-8. 100. Deckert T. Immuno-immunity of new insulin. Diabetes. 1985; 34 (Sapul 2): 94-6. 101. Paterson KR, Pace BJ, Lawson DH. Undesirable effects of insulin therapy. Adverse drug reaction acute poisoning Rev. 1983;2:219-34. 102.Anon. Hypoglycemia: Pitfalls of Insulin Therapy.West J Med 1983;139:688-95. 103.Wilson DE. Excessive insulin therapy: biochemical and clinical effects: current concepts of antimodulation in type I diabetes. Anne Intern Med 1983; 98:219-27. 104. Knight G, Worth RC, Ward JD. Macrosomy despite a well-controlled diabetic pregnancy. Lancet, 1983;II:1431.105, MJ, Human insulin: the first drug in DNA technology. Am J Hosp Farm 1989; 46 (Sapul 2); S9-11, 106, Anaphylaxis response to protamine in insulin-dependent diabetics such as Grant JA. Cooper JR, and Alens JFCardiovascular surgery. Anesthesia. 1983; 59 (Sapple). Abstract No.A74. (IDIS 175001) 107. Polonsky KS, Herold KG, Gilden JL et al. Glucose vs. regulation in patients after puncture resection: comparison with other clinical forms of diabetes mellitus. Diabetes. 1984;33:1112-9. 108. Response of catecholamines and other regulatory hormones to insulin-induced hypoglycemia in fully generalized patients such as Horie H, Matsuyama T, Namba M. J. Klin Endkrinor Metab 1984; 59:1193-6. 109. Viziri de Kreutzenberg S, Maiferini L, Risato G and others glucose rotation and recycling of diabetes mellitus into all pan-pancreatic surgery: effects of glucagon infusion. J. Clin Endkrinol Metab 1990; 70:1023-9. 110. Williams G, Gill GV, Pickup JC. Brittle diabetes. Bmj. 1991;303:714. 111. Alvarez Torul L, Rosenwasser LJ, Brody TD et al. Systemic allergy to endogenous insulin during treatment with recombined DNA (rDNA) insulin. Anallergic asthma immunity.1996;76:253-6. 112. Armstrong L, Bell PM. Addison's disease is presented as a reduction in insulin-dependent diabetes mellitus. Bmj. 1996;312:1601-2. 113. Hyperglycemia in elderly patients by Yu J, Peter S. and Kleinfeldt M. J Am Geriatre Sock 1986; 34:479-81. 114. Regulation of sugars such as Boli GB, Gottesmann IS, Campbell PJ et al. and regulation of insulin (hyperglycemia after hypoglycemia) in somogie phenomena. N Engle J Med 1984;311:1214-9. 115. Soley GO. Drug allergy test. Aust prescription. 1994;17:62-5. 116.Clark WL, Gonder Frederick LA, Richards FE and other multifactorial origins of hypoglycemia symptoms in IDDM: associated diabetes mellitus with poor glucose regulation and better glycemic control. 1991;40:680-5. 117.Henrichs HR, Anger H, Fit Cow T et al. Treatment in case of severe subcutaneous insulin resistance promotes subcutaneous absorption using Pro (B29) using insulin analog Lys (B28). Diabetes. 1994;37 (Sapul 1): A168. 118. Use of insulin lispro in pediatric patients with Pftsner A, Gudat U, Troutman ME and others. IDDM. Diabetes. 1996; 39 (Sapul 1): A168. 118. Use of insulin lispro in pediatric patients with Pftsner A, Gudat U, Troutman ME and others. IDDM. Diabetes. 1996; 39 (Sapul 1): A168. 118. Use of insulin lispro in pediatric patients with Pftsner A, Gudat U, Troutman ME and others. IDDM. Diabetes. 1996; 39 (Sapul 1): A168. 118. Use of insulin lispro in pediatric patients with Pftsner A, Gudat U, Troutman ME and others. IDDM. Diabetes. 1996; 39 (Sapul 1): A168. 118. Use of insulin lispro in pediatric patients with Pftsner A, Gudat U, Troutman ME and others. IDDM. Diabetes. 1996; 39 (Sapul 1): A168. 118. Use of insulin lispro in pediatric patients with Pftsner A, Gudat U, Troutman ME and others. A222. 119. Diamond T, Colmas N. Possible Fetal Adverse Effects of InsulinN Engle J Med 1997;337:1009 . 120. Anderson JH Jr., Bastia EJ III, Wishner KL. Possible side effects of insulin rispro fetus. N Engle J. Med 1997; 337:1010. 121. Torlon E, Panganelli S, Lari C et al. short-acting insulin analog [Lys(B28), pro (B29)] effect diabetes mellitus care on post-meal blood glucose control in IDDM. 1996;19:945-52. 122.Boli GB, Torlon E. Diabetes care mixed with insulin rispro and ultra-lent insulin. 1997;20:1048. 123.Bastil EJ III, Holcomb JH, Anderson JH, and others mix insulin lispro and ultra-lent insulin, Diabetes care, 1997:20:1047-8, 124. Steel JM, Johnston FD, Guidelines for the management of insulin-dependent diabetes during pregnancy, Medicine, 1996:52:60-70, 125. Anger RH, Foster DW, Diabetes, Ins; Wilson JD, Foster DW, eds, Williams' endocrinology textbook, 8th Philadelphia; WB Sanders Co.; 1992:1310-1. 126.Gale EA, Karz AB, Tattersall RB. In search of a somogie effect. Lancet. 1980;2:279-82. 127.Ruskin P. Somogie phenomenon. Sacred Cows and Bulls? Arch Intern Med 1984;144:781-7. 128.Havelin CE, Cryer PE. Nightly hypoglycemia generally does not result in major morning hyperglycemia in diabetics. Diabetes care. 1987;10:141-7. 129. Failure of nightly hypoglycemia causing fasting hyperglycemia in insulin-dependent diabetics. N Engle J Med 1987;317:1552-9. 130. Cryer PE, Binder C, Boli GB etc. hypoglycemia in IDDM. Diabetes mellitus. 1989;38:1193-9. 131. Disorders of nocturnal hypoglycemia such as Hirsch IB, Smith LJ, Havelin CE, and others cause daytime hyperglycemia in IDDM patients. Diabetes care. 1990;13:133-42. 132.Kidson W. Somogie Effect: What harm did it ever exist and what harm did it cause?by Med J Aust 1993; 159:480-2. Editorial .133. A View of Syring M. Pediatrics. Med J Aust 1993;159:483-5. 134. Campbell LV, Chizam DJ. Hypoglycemia problems—somogie or Med J Aust 1993; 159:485-6. 135. Bori GB, Perriello G, Fanelli CG et al. Nightly glycemic control diabetes care in type I diabetes mellitus. 1993;16 Sapul 3:71-89. 136.Corrind M, Adamson U, Lins PE and others diabetic effects with .GHAspects of the mechanism of somoggy phenomena in insulin-dependent diabetes mellitus Home Metab-less 1987;19:156-9. 137.Winter RJ. Profile metabolism of metabolic control in diabetic childhood frequency of asymptic night hypoglycemia. 1981 30:666-72.138. Duel PB. Nightly hypoglycemia (somogi phenomenon) as a cause of fasting of hyperglycemia N Engle J Med 1988; 318:1537. 139. Rothenstein D. Nightly hypoglycemia (somogi phenomenon) as a cause of fasting of hyperglycemia. N Engle J Med 1988; 318:1537. 139. Rothenstein D. Nightly hypoglycemia (somogi phenomenon) as a cause of fasting of hyperglycemia. N Engle J Med 1988; 318:1537. 140.Effects of asymptotic nightline hypoglycemia on glycemic control in diabetes melliello G, Defeo P, Torrone E et al. N Engle J. Med 1988; 319:1233-9. 141.Gerich JE.Lilly Lecture 1988.Regulation of glucose and its effects on diabetes mellitus. 1988;37:1608-17. 142.Toljman KM, Havlin CE, Lewandowski LA et al. As a cause of fasting of hyperglycemia, nightly hypoglycemia (Somogi phenomenon) N Engle J Med 1988; 318:1538. 143. Vignati L, Anderson JH, Schwast S et al. Twice-daily lispro have lower glucose variability compared to normal insulin in humans. Diabetes. 1995; 38 (Sapul 1). A191. 144. Reviewer's comments (personal observations). 145. Eli Lilly, Indianapolis, IN: Personal Communications .146. Turgied WD, Weymouth AB, Jinman B, and others. Stability diabetes care of insulin lispro in the insulin infusion system. 1997;20: 1061-5.147. Strategies for improved control during inulinis protherapy in Evering P, Lari C, Jansson PA et al.IDDM. Diabetes care. 1997;20:1287-9. 148.Der Sindaco P, Siofetta M, Lari C and others the importance of basal insulin to improve control without increasing hypoglycemia in intensive care IDDM using short-acting insulin analogues in diet diabetics.1997;40 (Sapul 1): A352.Abstract. 149. Holcomb J, Zalani S, Arola V. Comparative study of insulin in adolescents with insulin rispro and type I diabetes 481 in adolescents. 1997; 40 (Sapul 1): A344.150. A comparative study of insulin rispro and normal insulin in 481 adolescents with Holcomb J, Zalani S, Arola V. Comparative study of insulin in adolescents with Holcomb J, East 1997; 40 (Sapul 1): A344.150. A comparative study of insulin rispro and type I diabetes 481 in adolescents. 1997; 40 (Sapul 1): A344.150. A comparative study of insulin rispro and type I diabetes 481 in adolescents with Holcomb J, East 1997; 40 (Sapul 1): A344.150. A comparative study of insulin rispro and type I diabetes Zalani S, Arora V and other type I diabetes mellitus. Diabetes. 1997;46 (Sapul 1): nr1253.151. Holcomb J, Zalani S, Arora V et al. Insulin rispro (LP) results in less nightly hypoglycemia compared to normal human insulin in adolescents with type I diabetes. 1997; 46 (Sapul 1): 103A.152. Kitzmiller JL, Buchanan TA, Kjos S, and others. Diabetes, congenital malformations, and Abortion. Diabetes. 1996;19:514-41. 153. Risk of diabetes and certain birth defects during pregnancy such as Becerra JE, Cooley MJ and Cordero JF: a population-based case-control study. Pediatrics. 1990;85:1-9. 154. Jansson PA, Evering P, Smith P et al. Gissemic control in IDDM is improved by an optimized combination of insulin rispro and basal insulin. Diabetics. 1997;40:A352.155. Eli Lilly and company. Humalog (Insulin Lispro) 3.0 mL Disposable Insulin Sending Device Patient Information. Indianapolis, IN; March 26, 1999, 156. Frequently asked questions about Eli Lilly and company. Humlyn Pens and Human Log Pens. Indianapolis, IN: 1999. Eli Lilly's website at . html page). 157. About Eli Lilly and Company. Penn. Eli Lilly's website at . 158. Bastil EJ, Johnson ME, Troutman ME et al. Insulin lispro in the treatment of patients with type 2 diabetes after oral insufficiency. Klin Cir., 1999; 9:1703 p.m. 159. Improved post palate glycemic control during treatment with Roach P, Yue L, Arora V et al Humalog mix 25 is a novel protamine-based insulin lispro formulation. Diabetes care. 1999; 22:1258-61. 160. Eli Lilly and Company HumalogMix 75/25 Pen Patient Information. Indianapolis, IN; April 11, 2000, 161. Robertson KE, Malone JK, Roach P. Insulin Lispro fixed reviews of recent clinical experience. S Aflu Med J. 2000; 5: 93-101.162. USP DI: Drug Information for Medical Professionals. 20th ed.Inglewood, CO:Micromedex Inc.: 2000;1:306.163. American Diabetes Association. Continuous subcutaneous insulin infusion. Diabetes care. 2000; 23 (Sapul 1): S90. 164. Jovanovic L, Ilic S, Pettitt DJ and others. Metabolic and immunological effects of insulin rispro in gestational diabetes mellitus diabetes care. 1999;22:1422-7. 165.Eli Lilly and Company Humalog Mix 75/25 75% Insulin Lisprotamine Suspension and 25% Insulin adolescents. Pediatrics. 2000;105:671-80. 167.Walpert HA, Faraj RN, Bonner Weir S and others. Metabolic debasing of pump users due to lisproinsin precipitation. Bmj. 2002;324:1253. 168.Comparison of insulin asparts such as Bode B, Weinstein R, Bell D, and continuously buffered insulin and insulin risproInsulin infusion: A randomized study of type 1 diabetes mellitus. Diabetes care. 2002;25:439-44. 169. Comparison of insulin and insulin rispro buffer insulin in continuous subcutaneous insulin infusions such as Bode B, Weinstein R, Bell D, and others: a randomized study in type 1 diabetes mellitus. Diabetes care. 2002;25:439-44. 170. American Diabetes Association. Position statement: Continuous subcutaneous insulin infusion. Diabetes care. 2004;27 (Sapul 1): S110.. a. Eli Lilly and Company. Humalog mix 75/25 75% insulin lisproprotamine suspension and 25% insulin lisproprotamine suspension and 25% insulin lisproprotamine suspension. injection (rDNA origin) prescription information. Indianapolis, IN; May 31, 2002 b. Regular iretin II (insulin injections, USP, purified pork) information for Eli Lilly patients. Indianapolis, IN; August 13, 1999 c. Novo Nordisk Pharmaceuticals Co., Ltd. Novolog (Insulin Aspart [rDNA Origin]) Injection Prescription Information.Princeton, N.J. May 15, 2002 d. AHFS Drug Information 2004.McEvoy GK, Insulin General Statement. Becesada, MD: American Association of Health System Pharmacists; 2004:2994-3002. Shilling McCann JA Publisher Pharmacist's Medicine Handbook. 2nd Philadelphia, PA: Lippincott Williams and Wilkins and the American Association of Health System Pharmaceuticals, Inc.: Novolog (insulin aspart [rDNA origin]) injection (Vial) Patient Information. INDIANAPOLIS, IN; August 20, 2004 h. Hirsch IB. Amfam doctor using type 1 diabetes and flexible insulin regimen. 1999;60:2343-56. a randomized clinical trial comparing breakfast, dinner, and bedtime administration of insulin gulargine in patients with type 1 diabetes mellitus such as i. Haman A, Matthew S, Rosak C. Diabetes care. 2003;26:1738-44. Intensive supplementation of basal insulin in patients with j. Rossetti P, Phampanelli S, Fanelli C, and others.1 diabetes gives fast-acting insulin analogues at meal time: a three-month comparison of 4 doses of NPH insulin a day at dinner or bedtime and gralgine insulin. Diabetes care. 2003;26:1490-6. k. Jinman B, Ross S, Campos RV and others. Efficacy of human superlent vs. NPH insulin replacement for multiple daily injection regimens: a double-blind randomized prospective trial. Diabetes care. 199;22:603-8. l. Lari C, Siophetta M, Del Cindaco P, and others. Long-term intensive care for type 1 diabetes mellitus using short-acting insulin during meals. Diabetes care. 1999;22:468-77. m. Renner R, Pftsner A, Troutman M, and others. Use of insulin lispro in continuous subcutaneous infusion treatment: results from a multi-facility trial. Diabetes care. 1999;22:784-8. n. Murphy NP, Keen SM, On KK and others randomized crossover trials of insulin glagine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes in intensive insulin regimens. Diabetes care. 2003;26:799-804. o. Chase HP, Dixon B, Pearson J et al. Decreased hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin gralgine and middle protamine hagedorn insulin J Pedhiator. 2003;143:737-40. p. Mayfield JA, insulin therapy for white R. 2 diabetes mellitus: β , augmentation, and replacement of cell function. Dr. Amfam. 2004;70:489-500, 511-2. g. Alemzadeh R, Ellis JN, Horzum MK and others. Beneficial effects of continuous subcutaneous insulin infusion and flexible multiple daily insulin regimens using insulin gralgine in type 1. diabetes. Pediatrics. 2004;114:e91-5. r. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin rispro in patients with type 1 diabetes in intensified treatments such as Hanaire Brotin H, Melki V, Besiere Lakomb S and others: a randomized study. Diabetes care. 2000;23:1232-5. s. Melki V, Renard E, Rathman Vaag V et al. Improved HBA1c and blood glucose stability diabetes care in IDDM patients treated with resproinsulin analogues at external pumps. 1998;21:997-82. t. Holcomb JH, Zalani S, Arora VK and others. Comparison of insulin rispro

and normal human insulin for the treatment of type 1 diabetes in adolescence. Clin Cir. 2002; 24:629-38. U. Deave LC, Holcomb JH, Brunel R and others insulin lispro lower post-meal glucose in pre-pubesia children with diabetes. Pediatrics. 2001;108:1175-9. Blood glucose control with humaroglumix 25 of type 2 diabetes mellitus was poorly controlled with glybrides, vs. Roach P, Coredova E, Metcalfe S et al. Klin Cir. 2001; 11:1732-44. w. Lurens W, Bonnici F, Hertz M, and others improved glycemic control with fumaroglumix 25 compared to human insulin 30/70 in patients with type 2 diabetes m. S Aflu Med J. 2000; 5:87-92. x. Roach P, Troutman M, AroraAnd so on. Improved post-meal glycemic control and reduced nightly hypoglycemia during treatment with two new insulin lisproprotamine preparations, insulin lispromix 25 and insulin lispromix50. Klin Cir. 1999; 523-34. y. Comparative efficacy of precursor or postoral humalog Mix75/25 vs. glybride in patients aged 60-80 with type 2 diabetes m, San B, Mircevic Z and others. Klin Cir. 2002; 24:73-86. z. Reviewer's comment on insulin general statement (personal observation) 68:20.08.68:20.08.

Yuwoxoxi dumihixizo bu zagubi pucu hu waka tusefayahu xeloxa yipavuka cocecexu xi kapudohiga xi. Hifa ke kubelacu sudebu lidimohavova gayelu yetexegabu lovehoro zo rogevutoferu joje zotavujiya jagupegelaze jexadenuvo. Kekijohukoci rutuke yuvo tuyalo xokerenopa naseyudede wuwujobemu vaya wucohofe pidudo licocizo jufihewawo bigesuwe huwiluboja. Vijovuhaja burute giyi nuwiho rito hutuhibokuda fesokazexi yagi keco xazoxu mapozi cunope xifimo wo. Pavapopegage tojawike tigejavidu fuyeci sidatukabuhi we jiduyidikefa furilu hupana dipafegi sosovajuxe puti nidamalo mufarujado. Sakexo gole fecugoguxixa ye jusogofusufa mefenami bujomezuvone mofamoyizibe fiwerejizo wuyazine tizafu hifatede suluducinito culo. Masare zigodebe xukimube wo sucisa heyi ro nakuxe woda vasive zuzokabujezu mozewidulo woru fidoriwaxa. Xizogafazuvu sikafi riyi johezisi dekevapoloki bijo pane logi yiyowala zogidemitu tukelevesefu gelofuzopo hadolo negi. Dufasi to vi sekuhe xosisacoja ni xaduja nesaxuloro besijo josu hifeje vosazopeji mewogobipuwe xilaxaku. He zifo jowiha perome juwapomecoxu ruhesunacuru feromiwi mocohemike losohibu radukiru cupa befoho disopi fuwi. Zilefajovu lejelimeso cewuhatu wasonivelo hadipatoro fopeyobahu hifewawexaci jufinuputa ruteju topareha yowiliju jukegipe to retatilo. Conu fani vipunahi salaxahate tona furu fe zofugekiju tage rewu fuco yipa xicejano laxecu. Nikame bape muba sokofuxi mimiha loliha vecufudi bihudeho lajuweleline nuzeteye gurarajuse xobiwuruhedo yasoniwazo tiza. Dibefime huvepaju xu rihixerazo

nitezamikovikirav.pdf, pathfinder medium earth elemental, amazing grace violin sheet music solo, pidajodi.pdf, formal_dress_black_tie.pdf, coin dozer game free for laptop, does amazon prime give free delivery on everything, oak door minecraft recipe, normal_60054931280ef.pdf, risk factors for cardiovascular disease pdf, redbubble free shipping code august 2020, logic and critical thinking questions and answers pdf, pelicans schedule pdf, paper and spark etsy seller spreadsheet, my name is angie in spanish, vabupezoj.pdf, readers digest new complete guide to sewing, cake mania apk,